Author summary Why was this study done? Radical cure with primaquine or recently approved tafenoquine is required to clear the dormant liver parasites of vivax malaria. While single-dose tafenoquine overcomes the barrier of patient adherence to the current 7-day primaquine treatment, it costs more and requires screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency. While the impact of changing policies to tafenoquine after G6PD screening on transmission has been evaluated, the associated costs and cost-effectiveness will be important considerations for policymakers. What did the researchers find? Using an economic evaluation model coupled with a transmission model, we found that prescribing tafenoquine to vivax malaria patients without G6PD deficiency would be highly likely to be cost-effective in Brazil. Tafenoquine will be particularly cost-effective in settings where patient adherence to the current 7-day treatment is low and when paediatric tafenoquine is available
In this systematic review with meta-analysis and meta-regression, Daniel D. Hodgkiss and colleagues investigate exercise and aerobic capacity in individuals with spinal cord injury.
In a population-based, sibling-controlled cohort study Jiangwei Sun and colleagues explore the long-term risk of arrhythmias in patients with inflammatory bowel disease.
In a repeated-measures study conducted between 2018-2021 in 7 semi-rural parishes of Quito, Ecuador, Heather Kathleen Amato and colleagues aim to identify determinants of antibiotic resistant E.coli infection in children.